Vanda Pharmaceuticals shares in the red as skin disease test fails

Nasdaq
Vanda Pharmaceuticals' shares fell on the news its experimental skin drug tradipitant failed a phase 3 trial. (Nasdaq)

Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.

The drug was being assessed to see whether it could help pruritus (itching) in patients with in atopic dermatitis. In an update Tuesday, it seems it couldn’t: “The EPIONE study did not meet its primary endpoint in reduction of pruritus across the overall study population,” the biotech said in a statement.

Vanda's shares were down 2.5% premarket on the news.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

But it did see a glimmer of hope, adding that the antipruritic effect of tradipitant “was robust in the mild AD study population.” The company will now amend its trial to treat these patients, which it says is around 60% of the U.S. atopic dermatitis population.

The company reckons it can still tease out a win by moving the goalposts and says the flop may be due to distinct underlying pathology of mild versus more severe forms of atopic dermatitis.

Analysts at Jefferies said that, given this, it will amend its second test, known as EPIONE 2, to focus on mild atopic dermatitis with pruritus. But the firm warned in a note to clients Wednesday morning: “While we like this targeted approach, we caution post hoc analysis nature and unclear regulatory pathway.”

Suggested Articles

Sema4 announced an expanded, formal partnership with the state of Connecticut to provide COVID-19 testing to residents.

The FDA granted an emergency authorization to Abiomed’s Impella RP heart pump system for COVID-19 patients suffering from right-sided heart failure.

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…